JP7241080B2 - 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法 - Google Patents

抗ｔｍ４ｓｆ１抗体およびそれを使用する方法 Download PDF

Info

Publication number
JP7241080B2
JP7241080B2 JP2020534793A JP2020534793A JP7241080B2 JP 7241080 B2 JP7241080 B2 JP 7241080B2 JP 2020534793 A JP2020534793 A JP 2020534793A JP 2020534793 A JP2020534793 A JP 2020534793A JP 7241080 B2 JP7241080 B2 JP 7241080B2
Authority
JP
Japan
Prior art keywords
seq
tm4sf1
antibody
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020534793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534351A5 (https=
JP2020534351A (ja
Inventor
ジャミネット，ポール・エイ
ジャミネット，ショウ－チン・エス
ドボラク，ハロルド・エフ
プレスタ，レオナルド・ジー
Original Assignee
アンジーエックス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンジーエックス・インコーポレーテッド filed Critical アンジーエックス・インコーポレーテッド
Publication of JP2020534351A publication Critical patent/JP2020534351A/ja
Publication of JP2020534351A5 publication Critical patent/JP2020534351A5/ja
Priority to JP2023033463A priority Critical patent/JP2023071888A/ja
Application granted granted Critical
Publication of JP7241080B2 publication Critical patent/JP7241080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020534793A 2017-08-28 2018-08-28 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法 Active JP7241080B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023033463A JP2023071888A (ja) 2017-08-28 2023-03-06 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550994P 2017-08-28 2017-08-28
US62/550,994 2017-08-28
PCT/US2018/048402 WO2019046338A1 (en) 2017-08-28 2018-08-28 ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023033463A Division JP2023071888A (ja) 2017-08-28 2023-03-06 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2020534351A JP2020534351A (ja) 2020-11-26
JP2020534351A5 JP2020534351A5 (https=) 2021-10-07
JP7241080B2 true JP7241080B2 (ja) 2023-03-16

Family

ID=65526015

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020534793A Active JP7241080B2 (ja) 2017-08-28 2018-08-28 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法
JP2023033463A Pending JP2023071888A (ja) 2017-08-28 2023-03-06 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023033463A Pending JP2023071888A (ja) 2017-08-28 2023-03-06 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法

Country Status (8)

Country Link
US (3) US11208495B2 (https=)
EP (1) EP3675906A4 (https=)
JP (2) JP7241080B2 (https=)
CN (1) CN111565750B (https=)
AU (1) AU2018323470B2 (https=)
CA (1) CA3074111A1 (https=)
MX (1) MX2020002241A (https=)
WO (1) WO2019046338A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3003183A1 (en) 2015-11-24 2017-06-01 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia
US10279192B2 (en) 2016-11-17 2019-05-07 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual stimulation
MX2020002241A (es) * 2017-08-28 2020-09-03 Angiex Inc Anticuerpos anti-tm4sf y métodos de uso de los mismos.
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
EP3694464B1 (en) 2017-10-10 2025-12-10 Massachusetts Institute of Technology Systems for preventing, mitigating, and/or treating dementia
EP3807644A4 (en) * 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
MX2021010254A (es) 2019-02-27 2021-09-21 Angiex Inc Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
CN110734494B (zh) * 2019-10-30 2021-04-30 上海市第一人民医院 抗tspan8单克隆抗体及其用途
EP4126042A2 (en) * 2020-03-27 2023-02-08 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2021222783A1 (en) * 2020-05-01 2021-11-04 Angiex, Inc. Anti-tm4sf1 antibody drug conjugates and methods of using same
EP4188449A4 (en) * 2020-07-31 2025-12-17 Angiex Inc ANTI-TM4SF1 ANTIBODY AGENT CONJUGATES WITH CRISPABLE LINKERS AND METHOD FOR USE THEREMISH
WO2022046941A1 (en) * 2020-08-26 2022-03-03 Angiex, Inc. Antimitotic tetrapeptide-antibody conjugates and methods of using same
JP2024511479A (ja) * 2021-03-26 2024-03-13 アンジーエックス・インコーポレーテッド メイタンシン抗体コンジュゲートおよびそれを使用する方法
JP2024511478A (ja) * 2021-03-26 2024-03-13 アンジーエックス・インコーポレーテッド 抗ｔｍ４ｓｆ１抗体および免疫療法剤を含む組合せ剤ならびにそれを使用する方法
WO2022255401A1 (ja) * 2021-06-03 2022-12-08 国立大学法人 東京大学 Ｅｒｋ－ｍａｐｋ経路の異常な活性化に伴い発現する疾患マーカー
EP4349358A4 (en) * 2021-06-03 2025-05-28 Medpacto, Inc. TM4SF19 INHIBITOR AND ITS USES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184099A1 (en) 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US20040214872A1 (en) 2002-09-26 2004-10-28 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
WO2010073694A1 (ja) * 2008-12-25 2010-07-01 国立大学法人東京大学 抗tm4sf20抗体を用いた癌の診断と治療
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
JP6152090B2 (ja) 2011-04-21 2017-06-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 視神経脊髄炎を処置するための組成物および方法
CN102590531A (zh) * 2012-03-24 2012-07-18 广西壮族自治区肿瘤防治研究所 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法
MX384984B (es) * 2013-10-10 2025-03-14 Beth Israel Deaconess Medical Ct Inc Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
EP3071561B1 (en) 2013-11-22 2021-03-24 Sabre Therapeutics LLC Autotaxin inhibitor compounds
MX2020002241A (es) * 2017-08-28 2020-09-03 Angiex Inc Anticuerpos anti-tm4sf y métodos de uso de los mismos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184099A1 (en) 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular Cancer Therapeutics，Vol. 14, No. 8，2015年，P. 1868-1876

Also Published As

Publication number Publication date
US20220153860A1 (en) 2022-05-19
MX2020002241A (es) 2020-09-03
CN111565750A (zh) 2020-08-21
EP3675906A1 (en) 2020-07-08
US20220267461A1 (en) 2022-08-25
WO2019046338A1 (en) 2019-03-07
US11208495B2 (en) 2021-12-28
AU2018323470A1 (en) 2020-03-19
EP3675906A4 (en) 2021-05-26
JP2020534351A (ja) 2020-11-26
AU2018323470B2 (en) 2025-04-24
US20200270360A1 (en) 2020-08-27
JP2023071888A (ja) 2023-05-23
CN111565750B (zh) 2023-11-03
CA3074111A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
JP7241080B2 (ja) 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法
AU2022203601A1 (en) Therapeutic antibodies and their uses
AU2015292374B2 (en) Bispecific HER2 and CD3 binding molecules
JP6506280B2 (ja) 抗ｃｘｃｒ４抗体および抗体−薬剤コンジュゲート
CN104168914B (zh) Vegf/dll4结合剂及其应用
PT2486941T (pt) Anticorpos humanos que ligam a cxcr4 e utilizações dos mesmos
WO2017043613A1 (ja) 抗ｃｄ２６抗体と他の抗癌剤とを組み合わせた癌治療用組成物
US12428477B2 (en) Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
WO2022026915A9 (en) Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
US20230372518A1 (en) Antimitotic tetrapeptide-antibody conjugates and methods of using same
WO2020095866A1 (en) Her2 s310f specific antigen-binding molecules
US12606631B2 (en) Antibodies which bind human endothelin receptor a (ETAR)
US20250152730A1 (en) Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
CA3213164A1 (en) Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same
CN121335923A (zh) Ceacam1靶向抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210826

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230306

R150 Certificate of patent or registration of utility model

Ref document number: 7241080

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250